High-quality human biological samples are critical for advancing drug discovery, diagnostics, and precision medicine. In this webinar, three experts discuss best practices for ensuring specimen integrity, leveraging biobanking for oncology breakthroughs, and enriching clinical data for translational research.
From Clinic to Discovery: Maximizing Standard-of-Care Biospecimens
Meredith Osborn
Associate Director Product Management, Discovery Life Sciences
Precision medicine breakthroughs rely on uncovering and exploring novel biomarkers and mechanisms of action. Yet the reality is many patients aren’t getting tested for established biomarkers—let alone emerging research candidates. Discovery Life Sciences will discuss the limitations of standard of care data and share proven strategies for delivering research-ready samples enriched with meaningful data.
Key Determinants for Specimen Quality: Best practices for accurate results
Cathie Miller, PhD
Senior Director of Product Management, BioIVT
Advancements in drug discovery and diagnostics hinge on the quality of human biological specimens (HBS), as poor-quality specimens can undermine research validity, inflate costs, and delay progress. High-quality biospecimens are essential for reliable studies, clinical trials, and innovative treatments, with rigorous quality control, ethical compliance, and robust biobanking frameworks being non-negotiable. Providers like BioIVT exemplify industry standards through stringent quality measures, regulatory adherence, and diverse donor networks, ensuring specimens meet research needs. For example, BioIVT supports Antibody-Drug Conjugate (ADC) development by offering Ki67 staining on biospecimens, providing pre-stained blocks and custom screening projects to accelerate research. By partnering with trusted providers, researchers can mitigate risks, uphold scientific integrity, and accelerate breakthroughs in areas like liquid biopsy and targeted therapies.
How High-Quality Biospecimens Drive Oncology Breakthroughs
Katharina Krohn
Senior Director, Global Biobanks, Crown Bioscience
This presentation, led by Katharina Krohn, dives into the critical role of biospecimens in enabling clinically relevant oncology research. It covers best practices in biospecimen collection, storage, and quality assurance, including ISO-certified protocols and Crown Bioscience’s global biobank capabilities. We discuss how superior sample quality directly impacts research outcomes, showcasing real-world data from internal studies—such as the long-term stability of plasma cfDNA—and quantifying the financial benefits of low failure rates. This webinar will help researchers reduce variability, improve reproducibility, and unlock deeper biological insights for precision medicine.
Key Topics Include:
- Understand what data to expect from standard of care procedures and records, including a reality check on the progress of clinical adoption of personalized medicine.
- Explore strategic approaches used by Discovery Life Sciences to fill the data gap, providing high quality biospecimen ready to support advanced research needs.
- Understand the financial, scientific, and ethical implications of poor-quality biospecimens in drug discovery and diagnostic development.
- Identify key criteria for selecting reliable HBS providers, including quality control practices, regulatory compliance, and donor diversity.
- Biospecimen quality is essential—Proper collection, handling, and storage directly impact data accuracy, biomarker discovery, and reproducibility in oncology research.
- Ethically sourced, well-annotated biospecimens accelerate clinical relevance—Access to diverse, high-integrity samples with rich clinical metadata empowers more predictive and translational insights.
Presenters
Associate Director Product Management
Discovery Life Sciences
Senior Director of Product Management
BioIVT
Senior Director
Global Biobanks
Crown Bioscience
Production Partner
Discovery Life Sciences
BioIVT
Crown Bioscience
